{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066939","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.232618+00:00","generated_at":"2026-05-22T04:42:15.966818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Crinetics Q1 net loss $96.8M; cash $1.3B; paltusotine PDUFA Sept 25, 2025","bullets":["Net loss of $96.8M for Q1 2025 vs. $66.9M in Q1 2024, driven by higher R&D and SG&A costs.","Revenue $0.4M, down from $0.6M; primarily from Sanwa Kagaku licensing agreement.","Cash, equivalents, and investments $1.3B, expected to fund operations into 2029.","Paltusotine NDA under FDA review with PDUFA target action date Sept 25, 2025.","Phase 3 CALM-CAH study of atumelnant in CAH to begin H2 2025; R&D Day June 26."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066939","json":"https://secwatch.observer/filing/0000950170-25-066939.json","markdown":"https://secwatch.observer/filing/0000950170-25-066939.md","text":"https://secwatch.observer/filing/0000950170-25-066939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025066939/0000950170-25-066939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025066939/crnx-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:42:15.966818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}